Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination refers to the simultaneous administration of three distinct vaccines: the quadrivalent meningococcal conjugate vaccine (MenACWY), the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap), and the human papillomavirus (HPV) vaccine. This triad constitutes the standard adolescent immunization platform recommended by health authorities such as the CDC's Advisory Committee on Immunization Practices (ACIP) for children aged 11 to 12 years. While not available as a single fixed-dose combination product, these vaccines are routinely co-administered at separate injection sites during a single clinical visit. Clinical trials conducted by major vaccine developers have extensively evaluated this co-administration to confirm that the immune response to each component remains robust and that the safety profile is comparable to individual administration, ensuring high compliance with adolescent vaccination schedules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on meningococcal conjugate vaccine serogroups A, C, Y, W + tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine + human papillomavirus vaccine.